Amgen, Inc.

Pharma leaders may be disappointed as FTC scrutiny under the Biden administration is unlikely to ease with the incoming Trump administration. The FTC is expected to continue aggressive antitrust enforcement, including ongoing investigations into mergers like Amgen’s purchase of Horizon Therapeutics and Novo Holdings’ deal with Catalent. Additionally, the incoming administration may target pharmacy benefit managers (PBMs) and improper patent listings in the FDA’s Orange Book, aligning with Republican priorities to curb monopoly power.

Amgen's Phase 2 study of MariTide showed 20% weight loss over a year, but fell short of analyst expectations, leading to a stock drop. Concerns over side effects and high dropout rates also impacted the stock.

Amgen reports MariTide shows up to ~20% weight loss in obese/overweight patients without Type 2 diabetes and ~17% in those with Type 2 diabetes at 52 weeks, with no weight loss plateau observed, suggesting potential for further weight loss beyond 52 weeks.

Amgen to host a webcast on Nov. 26, 2024, at 5 a.m. PT to discuss Phase 2 study data of MariTide and its development program, featuring Robert A. Bradway and other senior management.

Hexagon Bio appoints Yujiro Hata to its Board of Directors, leveraging his expertise in oncology to advance its pipeline of novel ADCs with next-generation natural product-based payloads for cancer treatment.

Amgen’s surprise launch of a rival to Eylea in 2024 shakes up the US biosimilars market as it approaches its tenth anniversary, with competition to Stelara expected from 2025.

DelveInsight's 'Nasal Polyposis Pipeline Insight, 2024' report details the global development of 4+ Nasal Polyposis treatment therapies by 4+ key companies, including GlaxoSmithKline, Novartis, and AstraZeneca. Emerging therapies like Fasenra and Tezepelumab are expected to impact the market. The report covers clinical trials, mechanisms of action, route of administration, and market dynamics.

PMEA 2024, held on 21 November at the Sheraton Grand in London, recognized excellence in pharmaceutical marketing with 17 categories, including a new category for low- and middle-income countries. Sanofi and Regeneron won Excellence in Engaging and Educating Patients, Roche won Excellence in Low- and Middle-Income Countries, and Amgen was named PMEA Company of the Year.

Amgen and Pfizer appoint new Science executives to advance oncology and rare disease treatments. Dr Chris Boshoff becomes Pfizer's Chief Scientific Officer and President, Research & Development, while Dr Howard Chang joins Amgen as Senior Vice President of Research and Chief Scientific Officer.

The non-small cell lung cancer market is driven by increasing NSCLC cases, uptake of immune checkpoint inhibitors, emerging premium therapies, and awareness of mutations. DelveInsight's report covers current treatment practices, emerging drugs, market share, and forecasted market size from 2019 to 2032 in 7MM. Key companies and therapies include EMD Serono, Merck, AstraZeneca, Bristol-Myers Squibb, and therapies like M1774, C-TIL051, and Osimertinib. FDA approvals for Opdivo and Tagrisso in 2024 highlight advancements in treatment.